– USA, PA – Venatorx Pharmaceuticals, a clinical-stage pharmaceutical company, today announced the appointment of Tom Heyman to its Board of Directors as the Non-Executive Chairman.
“We are pleased to welcome Tom Heyman to our Board of Directors. As a highly respected and seasoned executive and board member, Tom brings a diverse breadth of industry experience across multiple disciplines that will benefit Venatorx as we continue to progress our pipeline of novel anti-infective therapy, “ said CEO, Chris Burns.
The company also announced that Independent Director, Dr. Mike Diem, has stepped down from the Board.
About Tomas J. Heyman
Tom Heyman brings more than 37 years of biopharmaceutical experience in corporate strategy, business development, and venture capital, as well as R&D, legal, and operational management experience to Venatorx’s Board. He spent his entire career at Johnson & Johnson and its affiliates both in the USA and in Belgium and retired from the company in September 2019. As president of JJDC, Johnson & Johnson’s corporate venture capital group, from 2015 until his retirement, Heyman managed approximately $1.5 billion in capital and oversaw investments in more than 120 companies. Before leading JJDC, he led business development for J&J’s pharmaceutical group, Janssen, for over 20 years, completing hundreds of licensing and M&A transactions. He was also the managing director of Janssen Pharmaceutica, Belgium, J&J’s largest subsidiary outside the U.S., and VP of licensing at Ortho Pharmaceutical, a J&J affiliate. Heyman currently serves as a member of the boards of directors of Xilio Therapeutics, Legend Biotech, Akero Therapeutics, OptiNose, and Invivyd (formerly Adagio Therapeutics Inc.).
“I believe Venatorx is well positioned to address the growing global crisis of antibiotic multi-drug resistant infections,” said Tom Heyman. “I’m very happy to join the Venatorx Board as Chairman as the Company continues to grow, achieve its scientific and regulatory milestones, and ultimately deliver new anti-infective therapies to patients in need.”
He earned a Master of Law degree from K.U. Leuven in Belgium and completed post-graduate studies in international law in Geneva, Switzerland, and post-graduate studies in business management at the University of Antwerp in Belgium.
About Venatorx Pharmaceuticals
Venatorx is a private, late-stage clinical pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections. Venatorx’s lead program, cefepime-taniborbactam, is a clinical-stage antibiotic that completed a Phase 3 study in adults with complicated urinary tract infections, including pyelonephritis. Based on positive results from the CERTAIN-1 clinical trial, the Company expects to submit a New Drug Application with the U.S. Food and Drug Administration for cefepime-taniborbactam in 2023. In October 2022, BARDA awarded a contract of up to $318M for the development and procurement of cefepime-taniborbactam for the treatment of melioidosis and multi-drug resistant infections. Venatorx is also developing an oral antibacterial, ceftibuten-ledaborbactam, for the treatment of cUTI, including pyelonephritis, caused by certain bacteria in adult patients with limited treatment options; this product is nearing completion of Phase 1.
SOURCE: https://www.venatorx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.